A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)
NCT ID: NCT04803006
Last Updated: 2025-07-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
18 participants
INTERVENTIONAL
2023-01-17
2030-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)
NCT04803058
A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation
NCT06019507
A Study of TCD601 in de Novo Renal Transplant Recipients
NCT05669001
A Dose Escalation Study in de Novo Renal Transplantation
NCT04311632
A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation
NCT06365437
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
TCD601administered with non-myeloablative conditioning and standard of care immunosuppression
TCD601
Investigational Product
Arm 2
TCD601administered with non-myeloablative conditioning and standard of care immunosuppression
TCD601
Investigational Product
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TCD601
Investigational Product
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female patients ≥ 18 to 65 years of age
* Recipient of a first renal transplant from a non-HLA identical, but at least haploidentical, ABO compatible living donor
Exclusion Criteria
* A history of cancer other than basal cell carcinoma of the skin or carcinoma in situ of the cervix
* Recipient with anti-HLA donor-specific antibody (DSA)
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ITB-Med LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tracy Killingsworth
Role: STUDY_DIRECTOR
Nefro Avillion
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCSF Connie Frank Transplant Center
San Francisco, California, United States
Columbia University Irving Medical Center
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TCD601A201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.